173943-92-5

Basic information

• Product Name: ethyl 4-hydroxy-4-(2-(2-hydroxyethyl)phenyl)piperidine-1-carboxylate
• Synonyms: ethyl 4-hydroxy-4-(2-(2-hydroxyethyl)phenyl)piperidine-1-carboxylate
• CAS NO: 173943-92-5
• Molecular Formula: C16H23NO4
• Molecular Weight: 293.35812
• EINECS: -0
• Mol File: 173943-92-5.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 455.8±45.0 °C(Predicted)
• Appearance: /
• Density: 1.214±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 13.94±0.20(Predicted)
• CAS DataBase Reference: ethyl 4-hydroxy-4-(2-(2-hydroxyethyl)phenyl)piperidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 4-hydroxy-4-(2-(2-hydroxyethyl)phenyl)piperidine-1-carboxylate(173943-92-5)
• EPA Substance Registry System: ethyl 4-hydroxy-4-(2-(2-hydroxyethyl)phenyl)piperidine-1-carboxylate(173943-92-5)

Safety Data

• Hazardous Substances Data: 173943-92-5(Hazardous Substances Data)

Usage

General Description

Ethyl 4-hydroxy-4-(2-(2-hydroxyethyl)phenyl)piperidine-1-carboxylate is a chemical compound with a complex structure containing a piperidine ring and an ester functional group. It is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. ethyl 4-hydroxy-4-(2-(2-hydroxyethyl)phenyl)piperidine-1-carboxylate has potential biological activity due to its structural resemblance to natural products and its ability to interact with various biological receptors. However, its specific pharmacological and toxicological properties have not been well-studied, and further research is needed to fully understand the effects and potential applications of this chemical in various industries.

Upstream product

• 1074-16-4 2-bromophenylethyl alcohol 
• 29976-53-2 N-ethoxycarbonyl-4-piperidone 

Downstream Products

• 180160-97-8 3,4-dihydrospiro[[2]benzopyran-1,4'-piperidine] 

Relevant articles and documents

Spiro-substituted piperidines as neurokinin receptor antagonists. II. Syntheses and NK2 receptor-antagonistic activities of N-[2-aryl-4-(spiro- substituted piperidin-1'-yl)butyl]carboxamides

In the course of our research on spiro-compounds as neurokinin receptor antagonists, N-[2-aryl-4-spiro-substituted piperidin-1'-yl)butyl]carboxamides were designed, based on YM-35375 (3) as a lead compound, and evaluated for NK2 receptor-antagonistic activities. Some derivatives inhibited the binding of radio-labeled neurokinin A to the NK2 receptor with IC50 values at the level of 10-9. Among these compounds, (±)-1'-[4-(N-benzoyl-N-methylamino)- 3-(3,4-dichlorophenyl)butyl]spiro[benzo[c]thiophene-1(3H), 4'-piperidine] 2- oxide (58, YM-38336) showed 10 times more potent NK2 receptor binding affinity than compound 3 (IC50 values of 8.9 and 84nM, respectively). It showed more potent inhibitory activity (ID50 20μg/kg (i.v.)) against [β- Ala8]-NKA(4 - 10)-induced bronchoconstriction in guinea pigs than compound 3 (ID50 41 μg/kg (i.v.)). This compound was also effective intraduodenally in the same model, exhibiting an ID50 value of 0.41 μg/kg.